Literature DB >> 18204481

What systems can and can't do.

T Kenakin1.   

Abstract

This commentary discusses a paper in this issue by Dr Jillian Baker on the antagonism of histamine H(2) receptors. It is an excellent example of the use of pharmacological principles to determine what systems can and can't do from the point of view of agonist-dependent antagonism. The most common model of antagonism, namely orthosteric, cannot discern agonist type; i.e. all agonists are blocked equally by a given orthosteric antagonist. Therefore, if quantitative assessment of antagonism unveils agonist dependence, then this is something an orthosteric mechanism cannot do and another mechanism must be considered. A simple alternative is a permissive allosteric model whereby the agonist and antagonist interact through conformational changes in the receptor protein. Under these circumstances, an agonist-antagonist dialogue can ensue whereby the nature of the agonist determines the magnitude of antagonist effect. Jillian Baker contrasts antagonist systems with historical data obtained for beta-adrenoceptors and the present data for histamine H(2) receptors where the simpler model of orthosteric antagonism suffices and thus shows how quantitative receptor pharmacology can be used to determine the molecular mechanism of antagonism.

Mesh:

Substances:

Year:  2008        PMID: 18204481      PMCID: PMC2267279          DOI: 10.1038/sj.bjp.0707677

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation.

Authors:  D A Hall
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  The receptor concept: pharmacology's big idea.

Authors:  H P Rang
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Allosteric modulation of G protein-coupled receptors.

Authors:  Lauren T May; Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 4.  Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.

Authors:  Barbara Bosier; Emmanuel Hermans
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

5.  A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties.

Authors:  Emeline L Maillet; Nadia Pellegrini; Celine Valant; Bernard Bucher; Marcel Hibert; Jean-Jacques Bourguignon; Jean-Luc Galzi
Journal:  FASEB J       Date:  2007-03-19       Impact factor: 5.191

6.  Determining the potency and molecular mechanism of action of insurmountable antagonists.

Authors:  Terry Kenakin; Stephen Jenkinson; Christian Watson
Journal:  J Pharmacol Exp Ther       Date:  2006-07-20       Impact factor: 4.030

7.  Evidence for a secondary state of the human beta3-adrenoceptor.

Authors:  Jillian G Baker
Journal:  Mol Pharmacol       Date:  2005-08-29       Impact factor: 4.436

8.  A study of antagonist affinities for the human histamine H2 receptor.

Authors:  J G Baker
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

Review 9.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.

Authors:  Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

Review 10.  Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates.

Authors:  Jillian G Baker; Stephen J Hill
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

View more
  3 in total

Review 1.  100 years of modelling ligand-receptor binding and response: A focus on GPCRs.

Authors:  David B Finlay; Stephen B Duffull; Michelle Glass
Journal:  Br J Pharmacol       Date:  2020-02-28       Impact factor: 8.739

2.  Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor.

Authors:  M Flores-Muñoz; N J Smith; C Haggerty; G Milligan; S A Nicklin
Journal:  J Physiol       Date:  2010-12-20       Impact factor: 5.182

3.  Different response patterns of several ligands at the sphingosine-1-phosphate receptor subtype 3 (S1P(3)).

Authors:  M Jongsma; J van Unen; P B van Loenen; M C Michel; S L M Peters; A E Alewijnse
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.